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Asthma is defined by airway inflammation and hyper-
responsiveness, and contributes to morbidity and mortality
worldwide. Although bronchodilation is a cornerstone of
asthma treatment, current bronchodilators become inef-
fective with time and with worsening asthma severity. We
investigated an alternative pathway for bronchodilation
that involves activating the airway smooth muscle enzyme,
soluble guanylate cyclase (sGC).
The pharmacologic sGC stimulator BAY 41-2272 or a
NO donor each triggered a dose-dependent bronchodila-
tion in precision cut human lung slices from healthy
donors and in mouse tracheal rings, whereas BAY 60-2770
was a less effective bronchodilator in these circumstances.
Neither NO nor BAY 41-2272 relaxed tracheal rings
obtained from sGC-/- mice. This established the NO-sGC
pathway can trigger bronchodilation in healthy airway. In
live animal studies, a single intra-tracheal administration
of either BAY 41-2272 or BAY 60-2770 reversed the air-
way hyper-responsiveness that had developed in mice with
allergic asthma and restored their normal lung function.
The sGC recovered from the mouse asthmatic lungs dis-
played three hallmarks of oxidative damage that render it
NO-insensitive, and identical changes were found to occur
in sGC obtained from human lung slices or from cultured
cells that had been exposed to low chronic NO. Our find-
ings reveal how allergic inflammation in asthma, and its
resulting airway inflammation and excessive NO produc-
tion, impede the natural NO-sGC-based bronchodilation
pathway, and suggest that pharmacologic sGC stimulants
or activators can provide a novel therapeutic approach to
achieve bronchodilation despite this loss.
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